Skip to main content
SpringerLink
Log in

Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations

  • Pharmacodynamics
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

Background and objectives

Opicapone is a novel third generation catechol-O-methyltransferase (COMT) inhibitor. The purpose of this study was to compare the levodopa pharmacokinetic profile throughout a day driven by the COMT inhibition either following repeated doses of opicapone or concomitant administration with entacapone.

Methods

A randomized, double-blind, gender-balanced, parallel-group study was performed in 4 groups of 20 healthy subjects each. Four subjects in each group received placebo during the entire study. Sixteen subjects in one group received placebo once daily for 11 days and on day 12, 200 mg entacapone concomitantly with each levodopa/carbidopa dose (three times separated by a 5-h interval). Sixteen subjects in each of the remaining three groups received respectively 25, 50, and 75 mg opicapone once daily for 11 days and on day 12, placebo concomitantly with each levodopa/carbidopa dose.

Results

Levodopa minimum plasma concentration (Cmin) for each levodopa/carbidopa dose and for the mean of all levodopa/carbidopa doses increased substantially with all active treatments (entacapone and opicapone) when compared to the control group (placebo), with values ranging from 1.7-fold (200 mg entacapone) to 3.3-fold (75 mg opicapone). No statistical difference was found for levodopa peak of systemic exposure (as assessed by maximum observed plasma concentration (Cmax)) between all active treatments and placebo. A significant increase in the levodopa extent of systemic exposure (as assessed by concentration-time curve (AUC)) occurred with all opicapone treatments in relation to placebo. No statistical difference was found for levodopa AUC when entacapone was compared to placebo. When compared to entacapone, both 50 and 75 mg opicapone presented a significant increase for the levodopa AUC. All active treatments significantly inhibited both peak (as assessed by Emax) and extent (as assessed by effect-time curve (AUEC)) of the COMT activity in relation to placebo. When compared to entacapone, all opicapone treatments significantly decreased the extent (AUEC) of the COMT activity due to a long-lasting and sustained effect. The tolerability profile was favorable for all active treatments.

Conclusion

Opicapone, a novel third generation COMT inhibitor, when compared to entacapone, provides a superior response upon the bioavailability of levodopa associated to more pronounced, long-lasting, and sustained COMT inhibition. The tolerability profile was favorable. On the basis of the results presented in this study and along with the earlier pharmacology studies, it is anticipated that opicapone adjunct therapy at the dosages of 25 and 50 mg will provide an enhancement in levodopa availability that will translate into clinical benefit for Parkinson’s disease patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Morgan JC, Sethi KD (2006) Emerging drugs for Parkinson’s disease. Expert Opin Emerg Drugs 11(3):403–417

    Article  CAS  PubMed  Google Scholar 

  2. Schapira AH, Emre M, Jenner P, Poewe W (2009) Levodopa in the treatment of Parkinson’s disease. Eur J Neurol: Off J Eur Fed Neurol Soc 16(9):982–989. doi:10.1111/j.1468-1331.2009.02697.x

    Article  CAS  Google Scholar 

  3. Dingemanse J (2000) Issues important for rational COMT inhibition. Neurology 55(11 Suppl 4):S24–S27, discussion S28-32

    CAS  PubMed  Google Scholar 

  4. Palma PN, Bonifácio MJ, Almeida L, Soares-Da-Silva P (2007) Restoring dopamine levels. In: Simth HJ, Simons C, Sewell RDE (eds) Protein misfolding in neurodegenerative diseases: mechanisms and therapeutic strategies. CRC Press, pp415-445

  5. Gomes P, Soares-da-Silva P (1999) Interaction between L-DOPA and 3-O-methyl-L-DOPA for transport in immortalised rat capillary cerebral endothelial cells. Neuropharmacology 38(9):1371–1380

    Article  CAS  PubMed  Google Scholar 

  6. Gervas JJ, Muradas V, Bazan E, Aguado EG, de Yebenes JG (1983) Effects of 3-OM-dopa on monoamine metabolism in rat brain. Neurology 33(3):278–282

    Article  CAS  PubMed  Google Scholar 

  7. Nutt JG, Woodward WR, Gancher ST, Merrick D (1987) 3-O-methyldopa and the response to levodopa in Parkinson’s disease. Ann Neurol 21(6):584–588. doi:10.1002/ana.410210610

    Article  CAS  PubMed  Google Scholar 

  8. Wade LA, Katzman R (1975) 3-O-methyldopa uptake and inhibition of L-dopa at the blood-brain barrier. Life Sci 17(1):131–136

    Article  CAS  PubMed  Google Scholar 

  9. Olanow CW, Stocchi F (2004) COMT inhibitors in Parkinson’s disease: can they prevent and/or reverse levodopa-induced motor complications? Neurology 62(1 Suppl 1):S72–S81

    Article  CAS  PubMed  Google Scholar 

  10. Bonifácio MJ, Palma PN, Almeida L, Soares-da-Silva P (2007) Catechol-O-methyltransferase and its inhibitors in Parkinson’s disease. CNS Drug Rev 13:352–379. doi:10.1111/j.1527-3458.2007.00020.x

    Article  PubMed  Google Scholar 

  11. Lang AE, Lees A (2002) Management of Parkinson’s disease: an evidence-based review. Mov Disord 17(Suppl 4):S45–S51

    Google Scholar 

  12. Brooks DJ (2004) Safety and tolerability of COMT inhibitors. Neurology 62(1 Suppl 1):S39–S46

    Article  CAS  PubMed  Google Scholar 

  13. Kiss LE, Ferreira HS, Torrao L, Bonifacio MJ, Palma PN, Soares-da-Silva P, Learmonth DA (2010) Discovery of a long-acting, peripherally selective inhibitor of catechol-O-methyltransferase. J Med Chem 53(8):3396–3411

    Article  CAS  PubMed  Google Scholar 

  14. Palma PN, Bonifácio MJ, Loureiro AI, Soares-da-Silva P (2012) Computation of the binding affinities of catechol-O-methyltransferase inhibitors: multisubstate relative free energy calculations. J Comput Chem 33(9):970–986

    Article  CAS  PubMed  Google Scholar 

  15. Bonifácio MJ, Torrão L, Loureiro AI, Wright LC, Soares-da-Silva P (2012) Opicapone: characterization of a novel peripheral long-acting catechol-O-methyltransferase inhibitior. Parkinsonism Relat Disord 18(S2):S125

    Google Scholar 

  16. Bonifácio MJ, Sutcliffe JS, Torrão L, Wright LC, Soares-da-Silva P (2012) Brain and peripheral levodopa pharmacokinetics in the Cynomolgus monkey following administration of opicapone, a novel catechol-O-methyltransferase inhibitor. Parkinsonism Relat Disord 18(S2):S125

    Google Scholar 

  17. Almeida L, Rocha J-F, Falcão A, Palma N, Loureiro AI, Pinto R, Bonifácio M, Wright LC, Nunes T, Soares-da-Silva P (2013) Pharmacokinetics, pharmacodynamics and tolerability of opicapone, a novel catechol-O-methyltransferase inhibitor, in healthy subjects: prediction of slow enzyme-inhibitor complex dissociation of a short-living and very long-acting inhibitor. Clin Pharmacokinet 52(2):139–151

    Article  CAS  PubMed  Google Scholar 

  18. Rocha JF, Almeida L, Falcao A, Palma PN, Loureiro AI, Pinto R, Bonifacio MJ, Wright LC, Nunes T, Soares-da-Silva P (2013) Opicapone: a short lived and very long acting novel catechol-O-methyltransferase inhibitor following multiple dose administration in healthy subjects. Br J Clin Pharmacol 76(5):763–775. doi:10.1111/bcp.12081

    Article  CAS  PubMed  Google Scholar 

  19. Ferreira JJ, Rocha JF, Falcão A, Pinto R, Nunes T, Soares-da-Silva P (2013) Effect of opicapone multiple-dose regimens on levodopa pharmacokinetics, motor response, and erythrocyte-COMT activity in Parkinson’s patients co-administered with levodopa/dopa-decarboxylase inhibitor. Mov Disord 28(Suppl 1):S154–S431

    Google Scholar 

  20. Ferreira JJ, Rocha JF, Santos A, Nunes T, Soares-da-Silva P (2012) The design of a double-blind, placebo- and active-controlled, multi-national phase-III trial in patients with Parkinson’s disease and end-of-dose motor fluctuations: Opicapone superiority vs. placebo and non-inferiority vs. entacapone. Mov Disord 27(Suppl 1):S118

    Google Scholar 

  21. Lees A, Costa R, Oliveira C, Lopes N, Nunes T, Soares-da-Silva P (2012) The design of a double-blind, placebo-controlled, multi-national phase-III trial in patients with Parkinson’s disease and end-of-dose motor fluctuations: opicapone superiority vs. placebo. Mov Disord 27(Suppl 1):S127

    Google Scholar 

  22. Silveira P, Vaz-da-Silva M, Almeida L, Maia J, Falcão A, Loureiro AI, Torrão L, Machado R, Wright LC, Soares-da-Silva P (2003) Pharmacokinetic-pharmacodynamic interaction between BIA 3-202, a novel COMT inhibitor, and levodopa/benserazide. Eur J Clin Pharmacol 59:603–609

    Article  CAS  PubMed  Google Scholar 

  23. Vieira-Coelho MA, Soares-da-Silva P (1996) Ontogenic aspects of liver and kidney catechol-O-methyltransferase sensitivity to tolcapone. Br J Pharmacol 117(3):516–520

    CAS  PubMed Central  PubMed  Google Scholar 

  24. Vieira-Coelho MA, Soares-da-Silva P (1999) Effects of tolcapone upon soluble and membrane-bound brain and liver catechol-O-methyltransferase. Brain Res 821(1):69–78

    CAS  PubMed  Google Scholar 

  25. Heikkinen H, Varhe A, Laine T, Puttonen J, Kela M, Kaakkola S, Reinikainen K (2002) Entacapone improves the availability of L-dopa in plasma by decreasing its peripheral metabolism independent of L-dopa/carbidopa dose. Br J Clin Pharmacol 54(4):363–371

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  26. Keranen T, Gordin A, Harjola VP, Karlsson M, Korpela K, Pentikainen PJ, Rita H, Seppala L, Wikberg T (1993) The effect of catechol-O-methyl transferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers. Clin Neuropharmacol 16(2):145–156

    Article  CAS  PubMed  Google Scholar 

  27. Rouru J, Gordin A, Huupponen R, Huhtala S, Savontaus E, Korpela K, Reinikainen K, Scheinin M (1999) Pharmacokinetics of oral entacapone after frequent multiple dosing and effects on levodopa disposition. Eur J Clin Pharmacol 55(6):461–467

    Article  CAS  PubMed  Google Scholar 

  28. Kurlan R, Nutt JG, Woodward WR, Rothfield K, Lichter D, Miller C, Carter JH, Shoulson I (1988) Duodenal and gastric delivery of levodopa in parkinsonism. Ann Neurol 23(6):589–595. doi:10.1002/ana.410230611

    Article  CAS  PubMed  Google Scholar 

  29. Mouradian MM, Heuser IJ, Baronti F, Fabbrini G, Juncos JL, Chase TN (1989) Pathogenesis of dyskinesias in Parkinson’s disease. Ann Neurol 25(5):523–526. doi:10.1002/ana.410250521

    Article  CAS  PubMed  Google Scholar 

  30. Stocchi F, Vacca L, Ruggieri S, Olanow CW (2005) Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study. Arch Neurol 62(6):905–910. doi:10.1001/archneur.62.6.905

    Article  PubMed  Google Scholar 

  31. Ingman K, Naukkarinen T, Vahteristo M, Korpela I, Kuoppamaki M, Ellmen J (2012) The effect of different dosing regimens of levodopa/carbidopa/entacapone on plasma levodopa concentrations. Eur J Clin Pharmacol 68(3):281–289. doi:10.1007/s00228-011-1121-5

    Article  CAS  PubMed  Google Scholar 

  32. Jorga K, Banken L, Fotteler B, Snell P, Steimer JL (2000) Population pharmacokinetics of levodopa in patients with Parkinson’s disease treated with tolcapone. Clin Pharmacol Ther 67(6):610–620. doi:10.1067/mcp.2000.106795

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department Research and Development, BIAL—Portela & Cª, S.A., À Av. da Siderurgia Nacional, 4745-457, S. Mamede do Coronado, Portugal

    José-Francisco Rocha, Ana Santos, Roberto Pinto, Nelson Lopes, Teresa Nunes, Lyndon C. Wright, Manuel Vaz-da-Silva & Patrício Soares-da-Silva

  2. Faculty of Pharmacy, University of Coimbra, Coimbra, Portugal

    Amílcar Falcão

  3. MedInUP—Center for Drug Discovery and Innovative Medicines, University Porto, Porto, Portugal

    Roberto Pinto, Manuel Vaz-da-Silva & Patrício Soares-da-Silva

Authors
  1. José-Francisco Rocha
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Amílcar Falcão
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ana Santos
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Roberto Pinto
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Nelson Lopes
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Teresa Nunes
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Lyndon C. Wright
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Manuel Vaz-da-Silva
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Patrício Soares-da-Silva
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Patrício Soares-da-Silva.

Electronic supplementary material

Below is the link to the electronic supplementary material.

ESM 1

(PDF 39 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rocha, JF., Falcão, A., Santos, A. et al. Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations. Eur J Clin Pharmacol 70, 1059–1071 (2014). https://doi.org/10.1007/s00228-014-1701-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-014-1701-2

Keywords

Search

Navigation